STANFORD UNIVERSITY

The CAVIAR trial demonstrated that alirocumab combined with rosuvastatin safely reduced LDL cholesterol levels by more than 50% in heart transplant patients within one year.

The META-AF study found that 78% of overweight/obese adults with atrial fibrillation who took metformin after catheter ablation remained free from AFib episodes for one year, compared to 58% in the usual care group.

Dr. George Tidmarsh, head of the FDA's drug center, abruptly resigned Sunday after federal officials began reviewing "serious concerns about his personal conduct."

Adaptyx Biosciences raised $14 million in seed financing led by Interlagos, bringing total funding to $23 million to develop its continuous multi-analyte molecular monitoring platform.

Excellergy secured $70 million in Series A funding to develop first-in-class trifunctional Effector Cell Response Inhibitors (ECRIs) for allergic conditions.

BioLegacy Evaluative Group has filed a provisional patent with the USPTO for an innovative air-driven intranasal drug delivery device targeting emergency and self-administered pharmaceuticals.

China's NMPA has approved the Nerivio® REN wearable device, marking the first and only approval of Remote Electrical Neuromodulation technology for migraine treatment in the country.

Ridge Biotechnologies emerged from stealth with an oversubscribed $25 million seed financing led by Sutter Hill Ventures to advance AI-enabled enzyme and targeted drug design for precision medicines.

Stanford University has been awarded a double-digit million dollar NIH grant to conduct a Phase II trial of Tiprelestat for pulmonary arterial hypertension, with patient enrollment expected to begin in mid-2026.

4DMedical has received FDA 510(k) clearance for CT:VQ, the world's first non-contrast CT-based ventilation-perfusion imaging software that eliminates the need for radioactive tracers.